• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    BIO-key International Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    3/27/25 8:30:25 AM ET
    $BKYI
    Computer Software: Prepackaged Software
    Technology
    Get the next $BKYI alert in real time by email
    bkyi20250327_8k.htm
    false 0001019034 0001019034 2025-03-27 2025-03-27
     
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
     
    Washington, D.C. 20549
     
    FORM 8-K
     
    CURRENT REPORT
     
    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
     
    Date of Report (Date of earliest event reported): March 27, 2025
     
    BIO-key International, Inc.
    (Exact name of registrant as specified in its charter)
     
    Delaware
    (State or other jurisdiction of
    incorporation)
    1-13463
    (Commission File Number)
    41-1741861
    (I.R.S. Employer Identification No.)
    101 Crawfords Corner Road, Suite 4116
    Holmdel, NJ 07733
    (Address of principal executive offices)
    (732) 359-1100
    (Registrant’s telephone number, including area code)
     
     
    Securities registered pursuant to Section 12(b) of the Act:
     
    Title of each class Trading Symbol(s) Name of each exchange on which registered
    Common Stock BKYI  Nasdaq Capital market
     
    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2 below):
     
    ☐
    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
     
    ☐
    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
     
    ☐
    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
     
    ☐
    Pre-commencement communications pursuant to Rule 13e-4(c) under Exchange Act (17 CFR 240.13e-4(c))
     
    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR 240.12b-2).
    Emerging growth company ☐
     
    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
     
     

     
     
    Item 2.02.         Results of Operations and Financial Condition.
     
    On March 27, 2025, BIO-key International, Inc. (the “Company”) issued a press release announcing its financial results for its fourth quarter and year ending December 31, 2024. A copy of the press release issued by the Company on March 27, 2025, is attached as Exhibit 99.
     
    The information, including the exhibit attached hereto, in this Current Report on Form 8-K shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as otherwise expressly stated in such filing.
     
     
    Item 9.01.         Financial Statements, Pro Forma Financial Information and Exhibit.
     
    (d)
    Exhibits. The following exhibit is furnished herewith:
     
     
    99.1
    Press Release, dated March 27, 2025, issued by the Company.
     
    104
    Cover Page Interactive Data File (embedded with the Inline XBRL document)
     
    2

     
     
    SIGNATURES
     
    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
     
    BIO-KEY INTERNATIONAL, INC.
    Date: March 27, 2025
    By:
    /s/ Cecilia C. Welch
    Cecilia C. Welch
    Chief Financial Officer
     
     

     
     
    EXHIBIT INDEX
     
                      
    Exhibit No. Description
       
    99.1 Press Release, dated March 27, 2025 issued by the Company.
     
     
    Get the next $BKYI alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $BKYI

    DatePrice TargetRatingAnalyst
    More analyst ratings